## Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9B Bet on Rare Disease Drug Vykat
Neurocrine Biosciences is making a major strategic move, announcing a $2.9 billion acquisition of Soleno Therapeutics to secure the only approved treatment for a devastating symptom of Prader-Willi syndrome. The deal, priced at $53 per share, represents a significant 34% premium over Soleno's recent closing price, signaling intense competition and high valuation for assets in the rare disease space. This acquisition instantly grants Neurocrine control over Vykat, a drug approved just this past March to treat hyperphagia—the relentless, life-threatening hunger that defines the genetic disorder.

The transaction centers on Vykat's unique market position. For patients with Prader-Willi syndrome, hyperphagia leads to dangerous overeating and obesity, and until this year, there was no pharmacologic treatment specifically approved for this core symptom. Soleno's success in gaining FDA approval for Vykat transformed it from a development-stage company into a highly attractive takeover target. Neurocrine's substantial premium payment reflects the strategic value it places on integrating this specialized, first-in-class therapy into its own neurology and endocrine-focused portfolio.

The deal pressures other biopharma firms with rare disease pipelines and highlights the premium valuations commanded by assets with clear regulatory approval and addressable patient populations. It also raises the stakes in the niche but critical market for Prader-Willi syndrome treatments, potentially accelerating further research and investment. For Neurocrine, the acquisition is a costly but direct path to commercializing a breakthrough therapy, though it now faces the execution risk of successfully launching and marketing Vykat to a highly specialized patient community.
---
- **Source**: STAT News
- **Sector**: The Vault
- **Tags**: M&A, Biopharma, Rare Disease, Prader-Willi Syndrome, Vykat
- **Credibility**: unverified
- **Published**: 2026-04-06 12:27:04
- **ID**: 51403
- **URL**: https://whisperx.ai/en/intel/51403